Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
GlobalData on MSN9h
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myelomaThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
clinicaltrialsarena on MSN7h
GSK reports positive outcomes from Phase III multiple myeloma treatment trialGSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.
GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
Medpage Today on MSN13h
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder CancerGSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...
Healthcare Asia on MSN15h
Pharmaceutical firms eye multiple myeloma amidst rising incidence ratesThe increase has been faster in women since 2000. The rising incidence of multiple myeloma (MM), particularly in relapsed and ...
In the end, all I could say is I have been there through sickness and your darkest times, and he didn’t say anything. I told ...
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback